skripsi - eprints.umm.ac.ideprints.umm.ac.id/48309/1/pendahuluan.pdf · iv kata pengantar...
TRANSCRIPT
i
SKRIPSI
MUHAMAD ANDRIYANTO FIRDAUS
STUDI PENGGUNAAN SEFOTAKSIM PADA
PASIEN SIROSIS HATI DENGAN SBP
(Spontaneous Bacterial Peritonitis)
(Penelitian Dilakukan di RSUD Dr.Saiful Anwar Malang)
PROGRAM STUDI FARMASI
FAKULTAS ILMU KESEHATAN
UNIVERSITAS MUHAMMADIYAH MALANG
2019
iv
KATA PENGANTAR
Assalamualaikum Wr. Wb.
Segala puji syukur penulis panjatkan kehadirat Allah SWT yang telah
melimpahkan berkah dan nikmat ke hamba-Nya, karena dengan pertolongan-Nya
skripsi yang berjudul Studi Penggunaan Sefotaksim Pada Pasien Sirosis Hati
Dengan SBP (Spontaneous Bacterial Peritonitis) (Penelitian dilakukan di
Rumah Sakit Umum Dr.Saiful Anwar Malang) dapat diselesaikan tepat waktu
dan dengan sebaik-baiknya.
Selanjutnya perkenankanlah penulis mengucapkan terima kasih yang tidak
terhingga kepada:
1. Bapak Drs. Didik Hasmono, M.S.,Apt selaku pembimbing I yang telah banyak
meluangkan waktu untuk membimbing dan memberi masukan ilmu, motivasi,
serta menginspirasi penulis selama menempuh pendidikan sampai
terselesaikannya tugas akhir ini.
2. Ibu Dr., Dra. Lilik Yusetyani, Apt., Sp.FRS. selaku Pembimbing II yang
selalu sabar dalam membimbing serta mengarahkan dan tidak sedikit
mengorbankan waktu untuk membimbing hingga tugas akhir ini dapat
diselesaikan dengan baik dan tepat waktu.
3. Ibu Ika Ratna Hidayati, S.Farm., M.Sc., Apt dan Ibu Firasti Agung M.S.,
M.Biotech., Apt selaku penguji I dan II yang telah memberikan masukan dan
saran untuk perbaikan tugas akhir ini.
4. Bapak Faqih Ruhyanudin M.Kep., Sp. Kep.MB selaku Dekan Fakultas Ilmu
Kesehatan Universitas Muhammadiyah Malang.
5. Ibu Dian Ermawati, M.Farm, Apt selaku Ketua Progam Studi Farmasi
Universitas Muhammadiyah Malang.
6. Direktur dan staf Rumah Sakit Umum Dr. Saiful Anwar Malang yang telah
membantu kelancaran penilitian skripsi.
7. Orang tua Ibu Sri Lestari dan Bapak Mohammad Ma’sum yang selalu
memberikan doa serta dorongan moril maupun materil yang tak terhingga.
x
DAFTAR ISI
Lembar Pengesahan ........................................................................................... ii
Lembar Pengujian ............................................................................................ iii
KATA PENGANTAR ....................................................................................... iv
RINGKASAN .................................................................................................... vi
ABSTRAK ....................................................................................................... viii
ABSTRACT ...................................................................................................... ix
DAFTAR ISI ...................................................................................................... x
DAFTAR GAMBAR ....................................................................................... xiii
DAFTAR TABEL ........................................................................................... xiv
DAFTAR LAMPIRAN .................................................................................... xv
DAFTAR SINGKATAN ................................................................................. xvi
BAB I PENDAHULUAN ................................................................................... 1
1.1 Latar Belakang....................................................................................... 1
1.2 Rumusan Masalah .................................................................................. 4
1.3 Tujuan Penelitian ................................................................................... 4
1.3.1 Tujuan Umum .........................................................................................4
1.3.2 Tujuan Khusus ........................................................................................4
1.4 Manfaat Penelitian ................................................................................. 4
1.4.1 Bagi Peneliti ..........................................................................................4
1.4.2 Bagi Rumah Sakit ...................................................................................4
BAB II TINJAUAN PUSTAKA ........................................................................ 5
2.1 Hati........................................................................................................ 5
2.1.1 Anatomi dan Strukstur Hati ...................................................................5
2.1.2 Sirkulasi Hati ..........................................................................................7
2.1.3 Fungsi Hati ..............................................................................................8
2.2 Sirosis Hati .......................................................................................... 11
2.2.1 Definisi .................................................................................................. 11
xi
2.2.2 Epidemiologi ......................................................................................... 11
2.2.3 Etiologi .................................................................................................. 12
2.2.4 Patofisiologi .......................................................................................... 12
2.2.5 Manifestasi Klinis ................................................................................. 13
2.2.6 Data Laboratorium ............................................................................... 14
2.2.7 Komplikasi ............................................................................................ 19
2.2.8 Managemen Penatalaksanaan Sirosis Hati ......................................... 23
2.2.9 Penatalaksanaan Komplikasi Pada Sirosis Hati ................................. 24
2.3 SBP (Spontaneous Bacetrial Peritonitis) .............................................. 27
2.3.1 Definisi .................................................................................................. 27
2.3.2 Epidemiologi ......................................................................................... 27
2.3.3 Etiologi .................................................................................................. 28
2.3.4 Faktor Resiko ........................................................................................ 29
2.3.5 Patofisiologi SBP.................................................................................. 29
2.3.6 Diagnosa Klinis .................................................................................... 31
2.3.7 Penatalaksanaan SBP ........................................................................... 32
2.4 Tinjauan Tentang Sefotaksim ............................................................... 41
2.4.1 Mekanisme Kerja Sefotaksim .............................................................. 42
2.4.2 Sifat Farmakodinamik Dan Farmakokinetik Sefotaksim ................... 42
2.4.3 Penggunaan Terapetik Sefotaksim pada SBP ..................................... 43
BAB III KERANGKA KONSEPTUAL........................................................... 46
3.1 Kerangka Konseptual ........................................................................... 46
3.2 Kerangka Operasional .......................................................................... 47
BAB IV METODE PENELITIAN ................................................................... 48
4.1 Rancangan Penelitian ........................................................................... 48
4.2 Populasi dan Sampel ............................................................................ 48
4.3 Bahan Penelitian .................................................................................. 49
4.4 Instrumen Penelitian ............................................................................ 49
4.5 Tempat dan waktu penelitian ............................................................... 49
4.6 Definisi Operasional ............................................................................ 49
4.7 Metode Pengumpulan Data ................................................................. 50
4.8 Analisa Data ........................................................................................ 51
xii
BAB V HASIL PENELITIAN ........................................................................ 52
5.1 Data Demografi Pasien ........................................................................ 53
5.1.1 Distribusi Berdasarkan Jenis Kelamin ................................................. 53
5.1.1 Distribusi Berdasarkan Usia ................................................................. 53
5.1.3 Distribusi Berdasarkan Status Pasien................................................... 54
5.2 Komplikasi .......................................................................................... 54
5.3 Profil Terapi Lainnya ........................................................................... 55
5.4 Pola Penggunaan Sefotaksim Pada Pasien Sirosis Hati Dengan SBP .... 55
5.4.1 Pola Penggunaan Terapi Sefotaksim .................................................. 55
5.3.2 Pola Penggunaan Terapi Sefotaksim Tunggal.................................... 56
5.3.3 Pola Penggunaan Terapi Sefotaksim Kombinasi ............................... 56
5.3.5 Lama Penggunaan Terapi Sefotaksim ................................................ 57
5.4 Lama Rawat Inap Pasien Sirosis Hati Dengan SBP .............................. 58
5.6 Kondisi Keluar Rumah Sakit (KRS) Pasien Sirosis Hati Dengan SBP .. 58
BAB VI PEMBAHASAN ................................................................................. 59
BAB VII KESIMPULAN DAN SARAN ......................................................... 76
7.1Kesimpulan ............................................................................................... 76
DAFTAR PUSTAKA ....................................................................................... 77
LAMPIRAN ..................................................................................................... 86
xiii
DAFTAR GAMBAR
Gambar Halaman
2. 1 Anatomi Hati. ......................................................................................... 5
2. 2 Hati Normal Dan Cedera Hati Kronis ..................................................... 6
2. 3 Aliran vena porta & Pasokan arteri ke hati .............................................. 7
2. 4 Patofisiologi sirosis hati........................................................................ 13
2. 5 Manifestasi klinis sirosis hati ................................................................ 14
2. 6 Patofisiologi asites................................................................................ 21
2. 7 Patofisiologi SBP. ............................................................................... 29
2. 8 Indikasi Antibiotik Profilaksis Pada Sirosis…………………................ 39
2. 9 Struktur Kimia Sefotaksim.……………………………………………..41
3. 1 Skema Kerangka konseptual…..…………………….......…………….. 46
3. 2 Skema Kerangka Operasional..……………………….......…………….47
5. 1 Skema sampel yang memenuhi kriteria inklusi dan eksklusi………….. 52
xiv
DAFTAR TABEL
Tabel Halaman
II. 1 Etiologi sirosis hati ................................................................................ 12
II. 2 Nilai normal pemerikasaan laboratorium ............................................... 18
II. 3 Managemen Terhadap Etiologi Sirosis Hati. ......................................... 24
II. 4 Bakteri penyebab SBP .......................................................................... 28
II. 5 Rejimen antibiotik yang direkomendasikan untuk mengobati SBP ........ 33
II. 6 Antibiotik Sefalosporin ......................................................................... 37
II. 7 Daftar nama obat sefotaksim di Indonesia ............................................. 45
V. 1 Distribusi berdasarkan jenis kelamin........................................................53
V. 2 Distribusi berdasarkan usia .................................................................... 53
V. 3 Distribusi berdasarkan status pasien ....................................................... 54
V. 4 Komplikasi penyerta pada pasien SBP ................................................... 54
V. 5 Terapi lainnya pada pasien SBP ............................................................. 55
V. 6 Pola penggunaan terapi sefotaksim pada pasien SBP ............................. 55
V. 7 Pola penggunaan terapi sefotaksim tunggal pada pasien SBP ................. 56
V. 8 Pola terapi sefotaksim kombinasi pada pasien SBP ................................ 56
V. 9 Pola switch sefotaksim pada pasien SBP ................................................ 57
V. 10 Lama penggunaan terapi sefotaksim pada pasien SBP ........................... 57
V. 11 Lama perawatan pada pasien SBP.......................................................... 58
V. 12 Pola penggunaan terapi sefotaksim pada pasien SBP ............................. 58
xv
DAFTAR LAMPIRAN
Lampiran Halaman
1 Daftar Riwayat Hidup ....................................................................... 86
2 Surat Pernyataan ............................................................................... 87
3 Surat Ijin Penelitian .......................................................................... 88
4 Surat Laik Etik ................................................................................. 89
5 Lembar Pengumpulan Data .............................................................. 90
6 Tabel Data Induk ............................................................................ 184
77
DAFTAR PUSTAKA
Ahmad, J., Friedman, S. L., & Dancygier, H. (2014). Mount Sinai Expert Guides-
Hepatology. https://doi.org/10.1002/9781118932759
Ahmad, J., Friedman, S. L., & Dancygier, H. (2014). Mount Sinai Expert Guides-
Hepatology. https://doi.org/10.1002/9781118932759
Aires, F. T., Ramos, P. T., & Bernardo, W. M. (2016). Efficacy of lactulose in the
prophylaxis of hepatic encephalopathy in cirrhotic patients presenting
gastrointestinal bleeding. Revista Da Associação Médica Brasileira, 62(3),
243–247. https://doi.org/10.1590/1806-9282.62.03.243
Allen, R. C., & Brown, S. P. (2017). Modified antibiotic adjuvant ratios can slow
and steer the evolution of resistance: co-amoxiclav as a case study. BioRxiv.
Retrieved from http://biorxiv.org/content/early/2017/11/10/217711.abstract
Anastasioua, J., & Williams, R. (2013). When to use antibiotics in the cirrhotic
patient? The evidence base. Annals of Gastroenterology, 26(2), 128–131.
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka,
J., … Gines, P. (2018). EASL Clinical Practice Guidelines for the
management of patients with decompensated cirrhosis. Journal of
Hepatology, 69(2), 406–460. https://doi.org/10.1016/j.jhep.2018.03.024
Apley, M. D., & Coetzee, J. F. (2013). Antimicrobial dug use in cattle.
Antimicrobial Therapy in Veterinary Medicine.
https://doi.org/10.1002/9781118675014
Bellot, P., Francés, R., & Such, J. (2013). Pathological bacterial translocation in
cirrhosis: Pathophysiology, diagnosis and clinical implications. Liver
International, 33(1), 31–39. https://doi.org/10.1111/liv.12021
Bernardi, M., Ricci, C. S., & Zaccherini, G. (2014). Role of human albumin in the
management of complications of liver cirrhosis. Journal of Clinical and
Experimental Hepatology, 4(4), 302–311.
https://doi.org/10.1016/j.jceh.2014.08.007
Bhatnagar, R., & Maskell, N. A. (2013). Treatment of Complicated Pleural
Effusions in 2013. Clinics in Chest Medicine, 34(1), 47–62.
https://doi.org/10.1016/j.ccm.2012.11.004
78
Bibi, S., Waquaruddin, A., Ambreen, A., Furqan, K.,Syed, E.A. (2015) Clinical,
Laboratory and Bacterial Profile of Spontaneous Bacterial Peritonitis in
Chronic Liver Disease Patients. Journal of the College of Physicians and
Surgeons Pakistan 2015, Vol. 25 (2): 95-99
Blackwell, E. R. M., Tyson, A. P., Vitalis, Z., & Papp, M. (2014). Bacterial
Infections in Cirrhosis Complimentary Contributor Copy, 36–52.
Bordbar, M., Shakibazad, N., Fattahi, M., Haghpanah, S., & Honar, N. (2018).
Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury
from methotrexate in pediatric leukemia. The Turkish Journal of
Gastroenterology, 29(2), 203–209. https://doi.org/10.5152/tjg.2018.17521
Bunchorntavakul, C., Chamroonkul, N., & Chavalitdhamrong, D. (2016).
Bacterial infections in cirrhosis: A critical review and practical guidance.
World Journal of Hepatology, 8(6), 307–321.
https://doi.org/10.4254/wjh.v8.i6.307
Cawcutt, K. A., & Peters, S. G. (2014). Severe sepsis and septic shock: Clinical
overview and update on management. Mayo Clinic Proceedings, 89(11),
1572–1578. https://doi.org/10.1016/j.mayocp.2014.07.009
Claforan Monograph, P. (2014). Claforan (cefotaxime) 1–41.
Dancygier, H. (2014). Spontaneous bacteria peritonitis. In: Ahmad, J., Friedman,
S.L., & Dancygier, H. Mount Sinai Expert Guides Hepatology. UK: John
Wiley & Sons, Ltd, 227-234
David, B.T. (2005). Remington. The Science and Practice of Pharmacy Edisi 21.
Philadelphia : Lippincot William.
Dever, J. B., & Sheikh, M. Y. (2015). Review article: Spontaneous bacterial
peritonitis-bacteriology, diagnosis, treatment, risk factors and prevention.
Alimentary Pharmacology and Therapeutics, 41(11), 1116–1131.
https://doi.org/10.1111/apt.13172
DiPiro J.T., Wells B.G., Schwinghammer T.L. and DiPiro C.V., (2015),
Pharmacotherapy Handbook, Ninth Edit., McGraw-Hill Education
Companies, Inggris.
79
Fernández, J., & Gustot, T. (2012). Management of bacterial infections in
cirrhosis. Journal of Hepatology, 56(SUPPL. 1), 1–12.
https://doi.org/10.1016/S0168-8278(12)60002-6
Fernández, J., Tandon, P., Mensa, J., & Garcia-Tsao, G. (2016). Antibiotic
prophylaxis in cirrhosis: Good and bad. Hepatology, 63(6), 2019–2031.
https://doi.org/10.1002/hep.28330
Giguère, S., John F. P., Patricia M. D. (2013). Antimicrobial dug use in cattle.
Antimicrobial Therapy in Veterinary Medicine.
https://doi.org/10.1002/9781118675014
Gkamprela, E., Deutsch, M., & Pectasides, D. (2017). Iron deficiency anemia in
chronic liver disease: Etiopathogenesis, diagnosis and treatment. Annals of
Gastroenterology, 30(4), 405–413. https://doi.org/10.20524/aog.2017.0152
Goodman & Gilman, (2014), Dasar Farmakologi Terapi, Edisi 10, Editor Joel.
G.Hardman & Lee E. Limbird, Konsultan Editor Alfred Goodman Gilman,
Diterjemahkan oleh Tim Alih Bahasa Sekolah Farmasi ITB, Penerbit Buku
Kedokteran EGC, Jakarta.
Gunawan Gan Sulistia, Rianto Setiabudy dan Nafrialdi. (2013). Farmakologi Dan
Terapi. Departemen Farmakologi Dan Terapeutik FKUI. Jakarta: Balai
Penerbit FKUI.
Halilovic, J., & Heintz, B. H. (2014). Antibiotic dosing in cirrhosis. American
Journal of Health-System Pharmacy, 71(19), 1621–1634.
https://doi.org/10.2146/ajhp140031
Hamdy Hassan, Ahmed ElBaz, Ramadan Essa, Dina Soliman (2015). Cefotaxime
Resistance in Treatment of Spontaneous Bacterial Peritonitis. Life Science
Journal, 12(12). https:// doi:10.7537/marslsj121215.16
Herawati, F., Surabaya, U., Umar, F., & Andrajati, R. (2011). Pedoman
Interpretasi Data Klinik, (January).
Himanshu, R. (2012). Comparative Study of Antimicrobial Activity of
Ceftriaxone in Combination With Sulbactam and Tazobactam Using Disc
Diffusion Method. International Research Journal of Pharmacy, 3(5), 331–
334.
Informasi Spesialite Obat Indonesia (ISO) Volume 49, (2014), Ikatan Sarjana
Farmasi Indonesia, Jakarta.
80
Irvan F. Febyan. Suparto. (2018). Sepsis dan Tata Laksana Berdasar Guideline
Terbaru. Anestesiologi Indonesia, X(1), 62–73.
Ivanova, I. I. (2016). Liver cirrhosis: New concepts. Scripta Scientifica Medica,
48(2), 9. https://doi.org/10.14748/ssm.v48i2.1481
Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., … Ginès,
P. (2014). Bacterial infections in cirrhosis: A position statement based on the
EASL Special Conference (2013). Journal of Hepatology, 60(6), 1310–1324.
https://doi.org/10.1016/j.jhep.2014.01.024
Jason Chang, P. E., Wong, G. W., Li, J. W. Q., Lui, H. F., Chow, W. C., & Tan,
C. K. (2015). Epidemiology and clinical evolution of liver cirrhosis in
Singapore. Annals of the Academy of Medicine Singapore, 44(6), 218–225.
Juza, R. M., & Pauli, E. M. (2014). Clinical and surgical anatomy of the liver: A
review for clinicians. Clinical Anatomy, 27(5), 764–769.
https://doi.org/10.1002/ca.22350
Kementrian Kesehatan RI. (2011). Pedoman Pelayanan Kefarmasian Untuk
Terapi Antibiotika Kementrian Kesehatan Republik Indonesia. Pedoman
Pelayanan Kefarmasian Untuk Terapi Antibiotik, 11.
Khurana, R. K. (2014). Autonomic Dysreflexia. Encyclopedia of the Neurological
Sciences (Vol. 1). https://doi.org/10.1016/B978-0-12-385157-4.00495-4
Kim, I. H., Kisseleva, T., & Brenner, D. A. (2015). Aging and liver disease.
Current Opinion in Gastroenterology, 31(3), 184–191.
https://doi.org/10.1097/MOG.0000000000000176
Komarala, E. P., Doshi, S., Thiyagarajan, S., Aslam, M., & Bahadur, D. (2018).
Studies on drug release kinetics and antibacterial activity against drug-
resistant bacteria of cefotaxime sodium loaded layered double hydroxide-
fenugreek nanohybrid. New Journal of Chemistry, 42(1), 129–136.
https://doi.org/10.1039/c7nj03622a
La Mura, V., Nicolini, A., Tosetti, G., & Primignani, M. (2015). Cirrhosis and
portal hypertension: The importance of risk stratification, the role of hepatic
venous pressure gradient measurement. World Journal of Hepatology, 7(4),
688–695. https://doi.org/10.4254/wjh.v7.i4.688
Lakshmi, R., Nusrin, K. S., Georgy, S. A., & Sreelakshmi, K. S. (2014). Role of
Beta Lactamases in Antibiotic Resistance: a Review. International Research
81
Journal of Pharmacy, 5(2), 37–40. https://doi.org/10.7897/2230-
8407.050207
Lee, Samuel S._ Moreau, Richard-Cirrhosis _ a practical guide to management-
Wiley-Blackwell (2015)
Longo, D. L., & Fauci, A. S. (2014). Harrison Gastroenterologi & Hepatologi.
Jakarta: EGC
Lovena, A., Miro, S., & Padang, M. D. (2017). Artikel Penelitian Karakteristik
Pasien Sirosis Hepatis di RSUP Dr . M . Djamil Padang. 100(1), 5–12.
Maeda, A., Takeda, K., Tsuruya, K., Miura, S., Toyonaga, J., Nakashita, S., …
Yasunaga, C. (2012). A Case of Cell-Free and Concentrated Ascites
Reinfusion Therapy Effective for Refractory Ascites in Spontaneous
Bacterial Peritonitis in a Renal Transplant Patient. Case Reports in
Nephrology and Urology, 2(2), 138–144. https://doi.org/10.1159/000343247
Mandorfer, M., & Reiberger, T. (2017). Beta blockers and cirrhosis, 2016.
Digestive and Liver Disease, 49(1), 3–10.
https://doi.org/10.1016/j.dld.2016.09.013
Mane, M., Priyanka, M., Piyush, P., Shivaraj, A., Aditya, A., Dany J. (2016).
Study of Frequency of Spontaneous Bacterial Peritonitis in Patients with
Alcoholic Liver Cirrhosis with Ascites. Postgraduate Medical Journal of
NAMS, 9(2), 45–49.
Masoud, M. S., Ali, A. E., & Nasr, N. M. (2014). Review Article Chemistry ,
classification , pharmacokinetics , clinical uses and analysis of beta lactam
antibiotics : A review. Journal of Chemical and Pharmaceutical Research,
6(11), 28–58.
McPhee, S.J. dan Hammer, G.D., (2014). Pathophysiology of Disease An
Introduction to Clinical Medicine, Seventh Edition. McGraw-Hill Education
Merkel, C., Montagnese, S., & Amodio, P. (2012). Functional Anatomy of Liver
Circulation. Functional Molecular Imaging in Hepatology, 3–13.
Mohammad, A., Elsamman, M., Zaghloul, A., Mohamed, H., & Mohammed, W.
(2018). Rifaximin plus cefotaxime versus cefotaxime alone in treatment of
spontaneous bacterial peritonitis in patients with cirrhosis. The Egyptian
Journal of Internal Medicine, 30(3), 154.
https://doi.org/10.4103/ejim.ejim_19_18
82
Moustafa, H. M., Basttawey, M. B., Eid, K. A., & Meguid, M. M. A. (2012). Oral
Levofloxacin Versus Intravenous Cefotaxime in the Treatment of Patients
with Spontaneous Bacterial Peritonitis : A Randomized Controlled Trial,
80(2), 71–78.
Muir, A. J. (2015). Understanding the Complexities of Cirrhosis. Clinical
Therapeutics, 37(8), 1822–1836.
https://doi.org/10.1016/j.clinthera.2015.05.507
Nadelson, J., Satapathy, S. K., & Nair, S. (2016). Glycated Hemoglobin Levels in
Patients with Decompensated Cirrhosis. International Journal of
Endocrinology, 2016. https://doi.org/10.1155/2016/8390210
Nusrat, S., Khan, M. S., Fazili, J., & Madhoun, M. F. (2014). Cirrhosis and its
complications: Evidence based treatment. World Journal of
Gastroenterology, 20(18), 5442–5460.
https://doi.org/10.3748/wjg.v20.i18.5442
Oladimeji, A. A., Temi, A. P., Adekunle, A. E., Taiwo, R. H., & Ayokunle, D. S.
(2013). Prevalence of spontaneous bacterial peritonitis in liver cirrhosis with
ascites. The Pan African Medical Journal, 15(August 2013), 128.
https://doi.org/10.11604/pamj.2013.15.128.2702
Ozougwu, J. C. (2017). Physiology of the liver. The American Journal of
Medicine, 16(2), 256–271. https://doi.org/10.1016/0002-9343(54)90342-3
Pacifici, G. M., & Marchini, G. (2017). Clinical pharmacology of Cefotaxime in
neonates and Infants : Effects and pharmacokinetics. International Journal of
Pediatrics, 5(6), 5023–5041. https://doi.org/10.22038/ijp.2017.26241.2244
Patasik, Y. Z., Waleleng, B. J., Wantania, F. (2015). Profil Pasien Sirosis Hati
Yang Dirawat Inap Di Rsup Prof . Dr . R . D . Kandou Manado Periode
Agustus 2012 –. 3(April), 3–8.
Pedersen, J. S., Bendtsen, F., & Møller, S. (2015). Management of cirrhotic
ascites. Therapeutic Advances in Chronic Disease, 6(3), 124–137.
https://doi.org/10.1177/2040622315580069
Pleguezuelo, M., Benitez, J. M., Jurado, J., Montero, J. L., & De La Mata, M.
(2013). Diagnosis and management of bacterial infections in decompensated
cirrhosis. World Journal of Hepatology, 5(1), 16–25.
https://doi.org/10.4254/wjh.v5.i1.16
83
Poovorawan, K., Pan-Ngum, W., White, L. J., Soonthornworasiri, N., Wilairatana,
P., Wasitthankasem, R., … Poovorawan, Y. (2016). Estimating the impact of
expanding treatment coverage and allocation strategies for chronic hepatitis c
in a direct antiviral agent era. PLoS ONE, 11(9), 1–19.
https://doi.org/10.1371/journal.pone.0163095
Pop, A., & Andreica, V. (2015). Infections and liver cirrhosis: A dangerous
liaison. Human and Veterinary Medicine, 7(4), 264–270.
Prin, M., Bakker, J., & Wagener, G. (2015). Hepatosplanchnic circulation in
cirrhosis and sepsis. World Journal of Gastroenterology, 21(9), 2582–2592.
https://doi.org/10.3748/wjg.v21.i9.2582
Purohit, P., Malek, S., Desai, K., & Sadadia, M. (2015). A study of bacteriological
profile of ascitic fluid in suspected clinical cases of spontaneous bacterial
peritonitis at a tertiary care hospital in India. International Journal of
Medical Science and Public Health, 4(4), 496.
https://doi.org/10.5455/ijmsph.2015.06052014101
QuickStats.,(2017). Death Rates for Chronic Liver Disease and Cirrhosis, By Sex
and Age Group Natinal Vital Statistics System, United States , 2000 and
2015, CDC (Centers for Disease Control and Prevention),
http://www.cdc.gov/mmwr/volumes/66/wr/mm6638a9.html, Diakses
tanggal 1 September 2018.
Rashid, H., & Rahman, M. (2015). Possible transfer of plasmid mediated third
generation cephalosporin resistance between Escherichia coli and Shigella
sonnei in the human gut. Infection, Genetics and Evolution, 30, 15–18.
https://doi.org/10.1016/j.meegid.2014.11.023
Rodrigo, L. (2017). Introductory Chapter: Treatment of Ascites Associated with
Cirrhosis and Its Complications. Ascites - Physiopathology, Treatment,
Complications and Prognosis. https://doi.org/10.5772/intechopen.70232
Rostkowska, K. A., Szymanek-Pasternak, A., & Simon, K. A. (2018).
Spontaneous bacterial peritonitis – therapeutic challenges in the era of
increasing drug resistance of bacteria. Clinical and Experimental
Hepatology, 4(4), 224–231. https://doi.org/10.5114/ceh.2018.80123
Runyon, B. A. (2016). Spontaneous bacterial peritonitis in adults: Treatment and
prophylaxis. UpToDate, 20, 1–21. https://doi.org/10.1007/s11920-014-0463
y
84
Sabdoz Monograph, P. (2013). Sandoz ciprofloxacin, 1–53.
Shi, L., Wu, D., Wei, L., Liu, S., Zhao, P., Tu, B., … Qin, E. (2017). Nosocomial
and Community-Acquired Spontaneous Bacterial Peritonitis in patients with
liver cirrhosis in China: Comparative Microbiology and Therapeutic
Implications. Scientific Reports, 7(March), 1–7.
https://doi.org/10.1038/srep46025
Sibulesky, L. (2013). Normal liver anatomy. Clinical Liver Disease, 2(SUPPL. 1),
2012–2014. https://doi.org/10.1002/cld.124
Suhail, M., Abdel-Hafiz, H., Ali, A., Fatima, K., Damanhouri, G. A., Azhar, E.,
… Qadri, I. (2014). Potential mechanisms of hepatitis B virus induced liver
injury. World Journal of Gastroenterology, 20(35), 12462–12472.
https://doi.org/10.3748/wjg.v20.i35.12462
Taherpour, A. A., Narian, D., & Taherpour, A. (2015). Structural relationships
and theoretical study of the free energies of electron transfer, electrochemical
properties, and electron transfer kinetic of cephalosporin antibiotics
derivatives with fullerenes in nanostructure of [R]·C n (R = cefadroxil, cefep.
Journal of Nanostructure in Chemistry, 5(2), 153–167.
https://doi.org/10.1007/s40097-014-0146-6
Tambunan A, Mulyadi Y, Kahtan MI. (2013). Karakteristik pasien sirosis hati di
RSUP Dr. Soedarso Pontianak periode Januari 2008 -Desember 2010. Jurnal
Mahasiswa PSPD FK Universitas Tanjungpura.;2(1):1-19.
Tasneem, H., Shahbaz, H., & Sherazi, B. A. (2015). Causes, management and
complications of ascites: a review. International Current Pharmaceutical
Journal, 4(3), 370–377. https://doi.org/10.1111/j.1468-0017.1987.tb00118.x
Tsiaoussis, G. I., Assimakopoulos, S. F., Tsamandas, A. C., Triantos, C. K., &
Thomopoulos, K. C. (2015). Intestinal barrier dysfunction in cirrhosis:
Current concepts in pathophysiology and clinical implications. World
Journal of Hepatology, 7(17), 2058–2068.
https://doi.org/10.4254/wjh.v7.i17.2058
Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014). Liver cirrhosis. The
Lancet, 383(9930), 1749–1761. https://doi.org/10.1016/S0140-
6736(14)60121-5
Udy, A. A., Roberts, J. A., Jeffrey, L. (2018.). Antibiotic Pharmacokinetic /
Pharmacodynamic Considerations in the Critically Ill.
85
Verma, R. K., Giri, R., Agarwal, M., & Srivastava, V. (2017). To study the
relation between spontaneous bacterial peritonitis and serum ascitis albumin
gradient in chronic liver disease patients, 5(8), 3654–3658.
Wasim, M., Biland, B., Idrees, M., Zeb, M., Waqar, M., Khan, M., … Ullah, R.
(2014). Assessment of risk factors and clinical presentations in a liver
cirrhotic state-Pakistan. World Applied Sciences Journal, 32(7), 1252–1257.
https://doi.org/10.5829/idosi.wasj.2014.32.07.8672
Wu, G. Y., & Pappano, A. J. (2016). Pocket handbook of GI
pharmacotherapeutics. https://doi.org/10.1007/978-1-59745-284-7